Presentations & Publications

Targeting frameshift mutations with a Listeria monocytogenes immunotherapy drives neoantigen-specific anti-tumor immunity in the MC38 and CT26 mouse tumor models

UPLOADED:

March 2, 2018

Agonism of the CD137 co-stimulatory pathway synergizes with the Listeria monocytogenes-based immunotherapy, axalimogene filolisbac, to promote durable tumor regression in a murine HPV+ tumor model

UPLOADED:

February 25, 2018

Neoantigens that fail to elicit measurable T cell responses following peptide immunization can control tumor growth when delivered using a Listeria-based immunotherapy platform

UPLOADED:

February 5, 2018

Targeting shared hotspot cancer mutations with a Listeria monocytogenes immunotherapy induce potent anti-tumor immunity

UPLOADED:

February 1, 2018

Immunotherapy: A New Strategy for the Treatment of Cervical Cancer

UPLOADED:

January 22, 2018

Neoantigens that fail to elicit measurable T cell responses following peptide immunization can control tumor growth when delivered using a Listeria-based immunotherapy platform

UPLOADED:

January 5, 2018

Targeting frameshift mutations with a Listeria monocytogenes immunotherapy drives neoantigen-specific anti-tumor immunity in the MC38 and CT26 mouse tumor models

UPLOADED:

January 5, 2018

Targeting shared hotspot cancer mutations with a Listeria monocytogenes immunotherapy induce potent anti-tumor immunity

UPLOADED:

January 4, 2018

Advaxis’ Listeria monocytogenes-based immunotherapies rapidly impair intratumoral regulatory T cell survival and function and promote effector T cell recruitment, activation and differentiation

UPLOADED:

November 13, 2017

ADXS-PSA immunotherapy increases the magnitude and quality of prostate cancer-antigenspecific T cell responses in patients with metastatic castration-resistant prostate cancer

UPLOADED:

November 13, 2017

STAY TUNED

Mailing List

Sign up for email alerts for Press Releases and Advaxis' breaking news.

SOCIAL

Follow Us

Stay up to date on the latest events, news, and happenings on Advaxis and Immunotherapy.